Does Zydus’ Promising CAPS Candidate Have An Edge Over Novartis’ Ilaris?

Potential In Chronic Inflammatory Diseases

20 Sep 2022

Zydus has established proof of concept for ZYIL1, a NLRP3 inflammasome inhibitor to treat cryopyrin-associated periodic syndromes, via Phase II trials in Australia. Will the oral drug have an upper hand over injectables like Novartis’ Ilaris?

Rare Disease Sign — Pharma Has Increased Focus On Rare Diseases • Source: Shutterstock

Zydus Lifesciences Limited recently announced achieving positive proof of concept in a Phase II clinical study of its NLRP3 inflammasome inhibitor ZYIL1 to treat cryopyrin-associated periodic syndromes (CAPS), a rare, hereditary, life-long spectrum of auto-inflammatory conditions.

The Phase IIa, prospective, single arm, open-label study in Australia to determine safety and tolerability profile of orally administered small molecule ZYIL1 for seven days was to be conducted in three subjects having CAPS

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Lupin CEO On Trump’s Most Favored Nation Policy, Tariffs, Firm’s Five-Year Plan

16 May 2025

• By Vibha Ravi

Lupin CEO Vinita Gupta speaks on Trump’s most favored nation policy, the Inflation Reduction Act’s “pill penalty” and other developments in the US, a major market for the company. The company also outlines a five-year plan focused on complex generics and technology platforms.